
Early and Late Phase Airway Hyperresponsiveness
After Aerosol Challenge of Antigen
Specific airway resistance(cmH2O/s)
16
14
12
10
8
6
4
2
0
Time (min.) post 5% OVA Challenge

Figure 1

Induction of Asthmatic Attack in Normal BALB/c Mice and Effect of Prophylactic C5 Inhibition

Group & Schedule:	day 1, 14	day 25, 29, 32	day 28, 29, 30	day 33
P. Control	Ova + Alum	135.8, 40mg/kg	1% OVA aerosol	5% OVA aerosol
Anti-C5	Ova + Alum	BB5.1, 40mg/kg	1% OVA aerosol	5% OVA aerosol
Steroid	Ova + Alum	Dex	1% OVA aerosol	5% OVA aerosol
N. Control	PBS + Alum	PBS	PBS	PBS

Figure 2a

The prophylactic treatment schedule



Figure 2b

Induction of Asthmatic Attack in Normal BALB/c Mice and Effect of Prophylactic C5 Inhibition



Figure 3

Effect of Therapeutic C5 Inhibition (Aerosol or IV) During Asthmatic Attack

Group & Schedule:	day 1, 14	Aerosol on day 28-30 & day 32	day 35	day 35
P.Control	Ova + Alum	1% ova on day 29-30, 5% on 32	5% OVA	IV or aerosol 135.8
Anti-C5	Ova + Alum	1% ova on day 29-30, 5% on 32	5% OVA	IV or aerosol BB5.1
Steroid	Ova + Alum	1% ova on day 29-30, 5% on 32	5% OVA	IV or aerosol Dex
N.Control	PBS + Alum	PBS on day 29-30, PBS on 32	PBS	IV or aerosol PBS

Figure 4a

Induction of Asthmatic Attack in Balb/c Mice





- Animals were randomized into 6 treatment groups prior next challenge

Figure 4b

Effect of Aerosol anti-C5 mAb Treatment During Asthmatic Attack



Figure 5a

Effect of Aerosol anti-C5 mAb Treatment During Asthmatic Attack (Continuous Measurement)



Figure 5b

Effect of IV anti-C5 mAb Treatment During Asthmatic Attack



Figure 6a

Effect of IV anti-C5 mAb Treatment During Asthmatic Attack (Continuous Measurement)



Figure 6b


Serum C5 Activity 6 hr. After Treatment
% C5 (Hemolytic) Activity
120
100
80
60
40
20
0
BB5.1-aerosol
135.8-aerosol
Dex-aerosol
BB5.1-iv
135.8-iv
Dex-iv
Treatment

Figure 7

Effect of Steroid and anti-C5 Treatment on BAL total WBC Count (5hr after OVA challenge and mAb treatment)



Fig. 8

Eosinophils are the predominant Inflammatory cells in BAL

Fig. 9A: **Non-immunized**

Fig. 9B **Control mAb**

Fig. 9C: **Steroid**

Fig. 9D: **Anti-C5**


BAL WBC Differential Analysis
BAL WBC Differential (%)
100
80
60
40
20
0
Macrophages
Eosinophils
Neutrophils
Lymphocytes
Control mAb
Steroid
Anti-C5 mAb
None-Immune
Treatment

Fig. 10

Effect of Steroid and anti-C5 Treatment on BAL Histamine Level (5hr after OVA challenge and mAb treatment)



Fig. 11

New Data: Effect of Steroid and anti-C5 Treatment on BAL MMP-9 Level (5hr after OVA challenge and mAb treatment)



Fig. 12

Steroid and Anti-C5 mAb Treatment Block the Production of TGF-beta During Asthmatic Attack



Fig. 13

Test the Direct & Immediate Bronchial Dilation Effect of C5 Inhibitor Or In Combination with Salbutamol During Wheezing (Provocation with Allergen)



Fig. 14

Fig. 15

Test the Direct & Immediate Bronchial Dilation Effect of C5 Inhibitor Or In Combination with Salbutamol During Wheezing